Search Results

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc.

Surface Oncology today reported financial results and corporate highlights for the second quarter 2023.

Surface Oncology, Inc. announced that both Institutional Shareholder Services and Glass, Lewis & Co. have recommended Surface stockholders vote “FOR” the adoption of Surface’s merger agreement with Coherus BioSciences, Inc.

Surface Oncology today reported financial results and corporate highlights for the first quarter 2023, as well as anticipated near-term milestones.

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.

Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.

Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact ® System in Japan beginning November 30, 2023.

Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.